# Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
Canonical URL: https://biopharmsignal.com/news/NERV/minerva-neurosciences-provides-first-quarter-2026-financial-results-and-business-updates
Ticker: NERV
Company: Minerva Neuroscience
Source: Minerva Neuroscience
Published: 2026-05-05 12:00 EST
Original Source URL: https://ir.minervaneurosciences.com
## Summary

Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug–drug interaction concerns with roluperidone and olanzapine Roluperidone remains the only late-stage

## Article Body
Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug–drug interaction concerns with roluperidone and olanzapine Roluperidone remains the only late-stage
## Recent Company News
- 2026-06-01 20:05 EST — [Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs](https://biopharmsignal.com/news/NERV/minerva-neurosciences-establishes-scientific-advisory-board-to-advance-development-of-roluperidone-and-future-pipeline-programs) — Source: Minerva Neuroscience
- 2026-05-18 20:05 EST — [Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/NERV/minerva-neurosciences-to-participate-in-the-2026-jefferies-global-healthcare-conference) — Source: Minerva Neuroscience
- 2026-05-05 12:00 EST — [Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/NERV/minerva-neurosciences-provides-first-quarter-2026-financial-results-and-business-updates) — Source: Minerva Neuroscience
- 2026-04-02 20:05 EST — [Minerva Announces Leadership Transition](https://biopharmsignal.com/news/NERV/minerva-announces-leadership-transition) — Source: Minerva Neuroscience
- 2026-03-31 20:05 EST — [Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia](https://biopharmsignal.com/news/NERV/minerva-neurosciences-announces-first-patient-screened-in-global-phase-3-confirmatory-trial-of-roluperidone-for-the-treatment-of-negative-symptoms-of-schizophrenia) — Source: Minerva Neuroscience
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)